Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease
File(s)apt.16086.pdf (1.03 MB)
Published version
Author(s)
Type
Journal Article
Abstract
BACKGROUND: The gastrointestinal microbiota has an important role in mucosal immune homoeostasis and may contribute to maintaining mucosal healing in Crohn's disease (CD). AIM: To identify changes in the microbiota, metabolome and protease activity associated with mucosal healing in established paediatric CD. METHODS: Twenty-five participants aged 3-18 years with CD, disease duration of over 6 months, and maintenance treatment with biological therapy were recruited. They were divided into a low calprotectin group (faecal calprotectin <100 μg/g, "mucosal healing," n = 11), and a high calprotectin group (faecal calprotectin >100 μg/g, "mucosal inflammation," n = 11). 16S gene-based metataxonomics, 1 H-NMR spectroscopy-based metabolic profiling and protease activity assays were performed on stool samples. RESULTS: Relative abundance of Dialister species was six times greater in the low calprotectin group (q = 0.00999). Alpha and beta diversity, total protease activity and inferred metagenomic profiles did not differ between groups. Pentanoate (valerate) and lysine were principal discriminators in a machine-learning model which differentiated high and low calprotectin samples using NMR spectra (R2 0.87, Q2 0.41). Mean relative concentration of pentanoate was 1.35-times greater in the low calprotectin group (95% CI 1.03-1.68, P = 0.036) and was positively correlated with Dialister. Mean relative concentration of lysine was 1.54-times greater in the high calprotectin group (95% CI 1.05-2.03, P = 0.028). CONCLUSIONS: This multiomic study identified an increase in Dialister species and pentanoate, and a decrease in lysine, in patients with "mucosal healing." It supports further investigation of these as potential novel therapeutic targets in CD.
Date Issued
2020-10-08
Date Acceptance
2020-08-24
Citation
Alimentary Pharmacology and Therapeutics, 2020, 52 (9), pp.1491-1502
ISSN
0269-2813
Publisher
Wiley
Start Page
1491
End Page
1502
Journal / Book Title
Alimentary Pharmacology and Therapeutics
Volume
52
Issue
9
Copyright Statement
© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Sponsor
Medical Research Council (MRC)
Commission of the European Communities
Imperial College Healthcare NHS Trust- BRC Funding
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32929796
Grant Number
MR/P002536/1
715662
RDA27
Subjects
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
Pharmacology & Pharmacy
BOWEL-DISEASE
FECAL CALPROTECTIN
ENDOSCOPIC ACTIVITY
MICROBIOTA
CHILDREN
DATABASE
SPECTROSCOPY
MANAGEMENT
STRATEGY
THERAPY
1103 Clinical Sciences
1115 Pharmacology and Pharmaceutical Sciences
Gastroenterology & Hepatology
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-09-14